Determinants for the spread of Panton-Valentine leukocidin positive Staphylococcus aureus in Africa

Determinants for the spread of Panton-Valentine leukocidin positive Staphylococcus aureus in Africa - STAPH-PVL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017107

Enrollment

822

Registered

2019-05-28

Start date

2019-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Susceptibility to PVL B95.6 U80.00

Interventions

Group 1: Cross-sectional study: Healthy volunteers will be recruited and screened for S. aureus colonization in the nose and throat. A questionnaire will be used to document risk factors for colonizat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. African living in Africa or Caucasian living in Europe; 2. Legal age (=18 years); 3. Signed written informed consent

Exclusion criteria

Exclusion criteria: 1. Known HIV infection; 2. Pregnancy; 3. Regular intake of systemic immunomodulatory drugs (e.g. TNFa antagonist, glucocorticoids etc.); 4. Symptomatic S. aureus infection

Design outcomes

Primary

Measure	Time frame
1. To compare the humoral immune response to PVL (i.e. antibodies, complement) between Africans and Caucasians (Work package 1); 2. To compare properties of the C5aR (i.e. avidity to PVL, amino acid sequence) between Africans and Caucasians (Work package 2); 3. To compare the cellular response to PVL (i.e. inflammasome activation, cytotoxicity) between Africans and Caucasians (Work package 3); 4. To build a sustainable capacity in African research centres to study aspects on the interaction of S. aureus with the human host (Work package 4).	—

Measure

Time frame

1. To compare the humoral immune response to PVL (i.e. antibodies, complement) between Africans and Caucasians (Work package 1); 2. To compare properties of the C5aR (i.e. avidity to PVL, amino acid sequence) between Africans and Caucasians (Work package 2); 3. To compare the cellular response to PVL (i.e. inflammasome activation, cytotoxicity) between Africans and Caucasians (Work package 3); 4. To build a sustainable capacity in African research centres to study aspects on the interaction of S. aureus with the human host (Work package 4).

—

Countries

Congo - Kinshasa, Gabon, Germany, Nigeria

Contacts

Public ContactFrieder Schaumburg

Institut für Medizinische Mikrobiologie, Universitätsklinikum Münster

frieder.schaumburg@ukmuenster.de0251-8352752

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026